Suppr超能文献

调节性树突状细胞抑制哮喘变应原特异性IgG1抗体反应的直接机制与间接机制的作用

Contributions of direct versus indirect mechanisms for regulatory dendritic cell suppression of asthmatic allergen-specific IgG1 antibody responses.

作者信息

Ma Yanna, Dawicki Wojciech, Zhang Xiaobei, Gordon John R

机构信息

Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

出版信息

PLoS One. 2018 Jan 2;13(1):e0190414. doi: 10.1371/journal.pone.0190414. eCollection 2018.

Abstract

IL-10-differentiated dendritic cells (DC10) can reverse the asthma phenotype in mice, but how they suppress the asthmatic B cell response is unclear. Herein we assessed the mechanism(s) by which DC10 and DC10-induced Treg affect IgG1 production in asthma. We observed a rapid decline in lung-resident OVA-specific IgG1-secreting B cells on cessation of airway allergen challenge, and intraperitoneal DC10 therapy did not amplify that (p>0.05). It did however increase the loss of IgG1-B cells from the bone marrow (by 45+/-7.2%; p≤0.01) and spleen (by 65+/-17.8%; p≤0.05) over 2 wk. Delivery of OVA-loaded DC10 directly into the airways of asthmatic mice decreased the lung IgG1 B cell response assessed 2 dy later by 33+/-9.7% (p≤0.01), while their co-culture with asthmatic lung cell suspensions reduced the numbers of IgG1-secreting cells by 56.5+/-9.7% (p≤0.01). This effect was dependent on the DC10 carrying intact allergen on their cell surface; DC10 that had phagocytosed and fully processed their allergen were unable to suppress B cell responses, although they did suppress asthmatic Th2 cell responses. We had shown that therapeutic delivery of DC10-induced Treg can effectively suppress asthmatic T and B cell (IgE and IgG1) responses; herein CD4+ cells or Treg from the lungs of DC10-treated OVA-asthmatic mice suppressed in vitro B cell IgG1 production by 52.2+/-8.7% (p≤0.001) or 44.6+/-12.2% (p≤0.05), respectively, but delivery of DC10-induced Treg directly into the airways of asthmatic mice had no discernible impact over 2 dy on the numbers of lung IgG1-secreting cells (p≥0.05). In summary, DC10 treatment down-regulates OVA-specific B cell responses of asthmatic mice. While DC10 that carry intact allergen on their cell surface can dampen this response, DC10-induced Treg are critical for full realization of this outcome. This suggests that infectious tolerance is an essential element in regulatory DC control of the B cell response in allergic asthma.

摘要

白细胞介素-10分化的树突状细胞(DC10)可逆转小鼠的哮喘表型,但它们如何抑制哮喘中的B细胞反应尚不清楚。在此,我们评估了DC10和DC10诱导的调节性T细胞影响哮喘中IgG1产生的机制。我们观察到气道过敏原激发停止后,肺内驻留的OVA特异性IgG1分泌B细胞迅速减少,腹腔注射DC10治疗并未增强这种减少(p>0.05)。然而,在2周内,它确实增加了骨髓中IgG1-B细胞的丢失(增加了45±7.2%;p≤0.01)和脾脏中IgG1-B细胞的丢失(增加了65±17.8%;p≤0.05)。将负载OVA的DC10直接递送至哮喘小鼠气道,2天后评估肺内IgG1 B细胞反应降低了33±9.7%(p≤0.01),而它们与哮喘肺细胞悬液共培养使IgG1分泌细胞数量减少了56.5±9.7%(p≤0.01)。这种效应取决于DC10在其细胞表面携带完整的过敏原;吞噬并完全处理了其过敏原的DC10无法抑制B细胞反应,尽管它们确实抑制哮喘中的Th2细胞反应。我们已经表明,治疗性递送DC10诱导的调节性T细胞可有效抑制哮喘中的T和B细胞(IgE和IgG1)反应;在此,来自DC10处理的OVA哮喘小鼠肺内的CD4+细胞或调节性T细胞分别在体外抑制B细胞IgG1产生52.2±8.7%(p≤0.001)或44.6±12.2%(p≤0.05),但将DC10诱导的调节性T细胞直接递送至哮喘小鼠气道在2天内对肺内IgG1分泌细胞数量没有明显影响(p≥0.05)。总之,DC10治疗可下调哮喘小鼠的OVA特异性B细胞反应。虽然在其细胞表面携带完整过敏原的DC10可减弱这种反应,但DC10诱导的调节性T细胞对于充分实现这一结果至关重要。这表明感染性耐受是调节性DC控制过敏性哮喘中B细胞反应的一个基本要素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8547/5749789/3360676911e9/pone.0190414.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验